Given that the NO–sGC–cGMP signaling pathway is disrupted in cardiovasculardiseases and heart failure, preclinical evidence strongly supports vericiguat’sability to restore this pathway, reinforcing its potential as a therapeuticoption for these conditions. The gene discussed is SGCB; the disease is heart failure.